Clinical Trial Detail

NCT ID NCT02270463
Title SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Stemline Therapeutics, Inc.
Indications

acute myeloid leukemia

Therapies

tagraxofusp-erzs

Age Groups: senior adult

Additional content available in CKB BOOST